GeneDx Holdings Corp vs YieldMax Universe Fund of Option Income ETFs — how do they compare? GeneDx Holdings Corp trades at $81.99 (market cap $2.44B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| WGS | YMAX | |
|---|---|---|
Market Cap | $2.44B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $167.51 | $13.26 |
52-Week Low | $34.51 | $7.27 |
Enterprise Value | $2.48B | — |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.
The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →